Market distribution of human insulin in hospitals in China 2018

Among the sampling hospitals in China, insulin glargine - a long-acting insulin analogue - held a share of 35 percent in human insulin and insulin analogues market in 2018. Insulin therapy is mainly used to treat type 1 diabetes in which pancreas no longer produce enough or any insulin to lower blood sugar level. The market size of human insulin and insulin analogs in China was projected to expand with a compound annual growth rate of 4.4 percent until 2030.

Market share of human insulin and insulin analogues in hospitals in China in 2018, by product

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until September 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

October 2019

Region

China

Survey time period

2018

Special properties

based on the sales figures from sampling hospitals

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Diabetes in China"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.